SFX by Ex Libris Inc.

Title:	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)
Source:	Blood [0006-4971] Schulman, Sam yr:2011

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Schulman, S. "Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism." The New England journal of medicine 368.8 (2013): 709-718.
description	2.	Schulman, S. "Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis." Circulation 129.7 (2013): 764-772.
description	3.	Hankey, Graeme J. "Dabigatran etexilate: a new oral thrombin inhibitor." Circulation 123.13 (2011): 1436-50.
description	4.	Kearon, S. "Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism." New England Journal of Medicine, The 361.24 (2009): 2342-2352.
description	5.	Agnelli, G. "Apixaban for Extended Treatment of Venous Thromboembolism." The New England journal of medicine 368.8 (2012): 699-708.
description	6.	Connors, Jean M. "Extended treatment of venous thromboembolism." The New England journal of medicine 368.8 (2013): 767-769.
description	7.	Merli, V. "Rivaroxaban for thromboprophylaxis in acutely ill medical patients." The New England journal of medicine 368.6 (2013): 513-523.
description	8.	Key, Nigel S. "Current treatment of venous thromboembolism." Arteriosclerosis, thrombosis, and vascular biology 30.3 (2010): 372-375.
description	9.	Tullett, J. "Trial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (." BMC cardiovascular disorders 13.1 (2013): 16-16.
description	10.	Lassen, M R R. "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement." Journal of thrombosis and haemostasis 5.12 (2008): 2368-75.
description	11.	Mertz, D. "Outcomes of early switching from intravenous to oral antibiotics on medical wards." The Journal of Antimicrobial Chemotherapy 64.1 (2009): 188-188.
description	12.	Bontempo, Franklin A A. "Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia." American journal of hematology 83.5 (2008): 411-5.
description	13.	Genzen, Jonathan R R. "Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing." American journal of clinical pathology 124.4 (2005): 586-93.
description	14.	Eriksson, Harry R I. "Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial." The lancet 370.9591 (2007): 949-56.
description	15.	Connolly, Stuart J. "Dabigatran versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine, The 361.12 (2009): 1139-51.
description	16.	Bauersachs, R. "Oral rivaroxaban for symptomatic venous thromboembolism." The New England journal of medicine 363.26 (2010): 2499-2510.
description	17.	Prins, Martin H. "Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials." The Lancet Haematology 1.1 (2014): 37-46.
description	18.	Agnelli, G. "Oral Apixaban for the Treatment of Acute Venous Thromboembolism." The New England journal of medicine 369.9 (2013): 799-808.
description	19.	Goldhaber, Samuel Z. "Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients." The New England journal of medicine 365.23 (2011): 2167-2177.
description	20.	Wallentin, J. "Apixaban versus Warfarin in Patients with Atrial Fibrillation." The New England journal of medicine 365.11 (2011): 981-992.